MYND Life Sciences Announces Funding for Psilocybin Research in Neuroinflammation

R&D project on the benefits of psilocybin in the treatment of brain diseases

VANCOUVER, BC, November 30, 2021 / CNW / – MYND Life Sciences Inc. (“MYND“or the”Society“) (CSE: MYND) (OTC: MYNDF) is pleased and extremely grateful to recognize the financial contribution of the Government of Canada towards an important component of its research and development on the positive effects of psilocybin on the treatment of brain diseases.

Mynd Life Sciences Inc. (CNW Group / Mynd Life Sciences Inc.)

MYND Life Sciences will benefit from advisory services and up to $ 45,600 in financing National Research Council of the Canadian Industrial Research Assistance Program (NRC IRAP) to support a prescribed research and development project that will take place from November 2021 To March 2022.

“We are very pleased with the support of the government of Canada, both from a business advisory point of view, as well as valuable financial support, ”said Dr. Lyle Oberg, MD, CEO, MYND Life Sciences. “We take a holistic and measured approach to harnessing private capital investment, invaluable academic research infrastructure and advice backed by funding from major government search engines to tackle some of the most serious diseases of the brain and system.” central nervous. “

The project is called Phytochemical-analogue (s) as a novel method for the management of treatment-resistant depression. The goal of research and development is to determine how psilocybin analogues target a particular genetic pathway to modulate brain function.

“This support through NRC IRAP is timely and will enable an important part of our comprehensive approach to creating new innovations to improve the lives of people with diseases of the central nervous system,” said Dr. Wilfred Jefferies, Scientific Director, MYND Life Sciences.


MYND Life Sciences Inc. is a medical biotechnology drug research and development company focused on the development, diagnostics and vaccines of novel psilocybin-based drugs and neuropharmaceuticals. The Company advances pharmaceutical products through rigorous scientific and clinical trials, while diligently patenting and protecting its intellectual property. For more information and to subscribe to the MYND mailing list, please visit

Dr. Lyle Oberg, Managing Director, CEO
Email: [email protected]

Forward-looking statements

This press release contains forward-looking statements and information within the meaning of applicable securities laws. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates” , “Intention”, “” anticipates “or” does not anticipate “, or” believes “, or variations of these words and expressions or states that certain actions, events or results” could “,” could “,” would be “,” could “or” would “be made, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause the results, performance or achievements to be made. MYND’s actual results are materially different from the future results, performances or achievements expressed or implied by the forward-looking statements or information contained in this press release.

The risks, uncertainties and other factors involved in forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and accepts no responsibility for the adequacy or accuracy of the contents of this press release.

None of the securities issued under the Offer will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in United States no registration or an applicable exemption from the registration requirements of the 1933 Act. This press release does not constitute an offer to sell or a solicitation of an offer to buy and there will be no sale of securities in a state where such an offer, solicitation or sale would be illegal.



View original content to download multimedia:

SOURCE Mynd Life Sciences Inc.



View original content to download multimedia:

About Edward Fries

Check Also

Senate panel approves Huizenga’s NRTF funding bill

Measure includes 13 projects in Kent and Ottawa counties LANSING, Mich. – The Senate Appropriations …